Eli Lilly And Company ((LLY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Eli Lilly and Company, in collaboration with Tango Therapeutics, is conducting a Phase 1/2 clinical study titled Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss. The study aims to evaluate the safety, tolerability, and preliminary antitumor activity of TNG456, a selective PRMT5 inhibitor, both as a monotherapy and in combination with abemaciclib in patients with advanced solid tumors exhibiting MTAP loss. This research is significant as it explores new treatment avenues for challenging cancer types.
The study tests two interventions: TNG456, a selective PRMT5 inhibitor, and abemaciclib, a kinase inhibitor. TNG456 is administered orally and is designed to target tumors with MTAP loss, potentially offering a novel therapeutic option for these patients.
This interventional study employs a non-randomized, sequential intervention model with no masking. It begins with a dose escalation phase followed by a dose expansion phase, focusing on treatment as its primary purpose.
The study began on January 24, 2025, with its primary completion date yet to be announced. The latest update was submitted on August 28, 2025, indicating ongoing recruitment and progress in the study.
The study’s progress could positively influence Eli Lilly’s stock performance by showcasing its commitment to innovative cancer treatments. This update may bolster investor confidence, especially as the company competes in the oncology sector. The involvement of Tango Therapeutics also highlights a collaborative approach to tackling complex cancer challenges.
The study is currently recruiting, with further details available on the ClinicalTrials portal.